Pfizer’s unpredictable move just after the ‘no deal’ with BioNTech assumption

Introduction

Pfizer is a biotechnology corporation and a leading multinational pharmaceutical company, building its recognition since 1849, and is known for its vaccines and medicines and their effectiveness. The company is ruling in the areas of rare disease, internal medicine, immunology and oncology. Pfizer is well known for its innovation like popular COVID-19 vaccine and Lipitor. The company’s scientific advancements and valuable engagements in manufacturing, distribution, development and research are a huge contribution to the healthcare sector.

Novavax, Inc. is a leading biotechnology company known for marketing and establishing vaccines for extreme conditions. The company is famous for Matrix-M adjuvant and protein-related nanoparticle technology, which stimulates the immune system. Novavax keep on elevating its platform to produce innovative and effective vaccines mainly for COVID-19.

Announcement

After continuously being in the limelight for distancing and denying the deal with BioNTech, Pfizer comes with totally different and confirmed news of its worth $30 million partnership with Novavax. The rumours still haven’t met any conclusion, but this totally new news shifted the interest now to this million-dollar partnership.

Deal

Pfizer will bring a total of $500 million to the table for sales and development success, whereas Novavax will also be liable to pay royalties (single digit) on net sales profit. In return of this valuable investments, Pfizer will get a legal authority, the right to Novavax’s Matrix-M adjuvant technology. This technology utilises naturally occurring compounds from soapbark trees. This helps leverage the body’s immune response rate.

The use of this technology can apply to two disease spaces; apart from this, neither of the companies has yet clarified whether there are any programs or not.

Novavax’s partnership strategies

This recent deal by Novavax has come along with the double-thought environment towards vaccines, which is fully covered with policy news and antagonistic rhetoric from Trump’s rules. The shocking and adverse news regarding vaccines has made headlines since the director of the FDA’s Center for Biologics Evaluation and Research, Vinay Prasad, pointed out death of 10 children due to COVID-19 vaccines without any proof that the company has found it difficult to choose a deal for the same.

Whatsoever be the politics cooking within different regions, the healthcare domain is facing the storm in many cases. A responsible and mature deal is what Novavax is seeking. This recent deal marks the company’s resilience and dedication to trust and proves its effective vaccine power to stay well prepared for future possibilities.